As the COVID-19 pandemic worsens, the clinical cancer community is grappling with how to continue providing access to experimental but potentially lifesaving therapies while keeping immunocompromised patients safe. To that end, cancer centers are making changes to their clinical trial programs, while pharmaceutical companies are deciding how-or whether-trials should continue.
keywords
author
year ⏰ 2020
issn 🗄
volume
number
page
citedbycount 0
download 🔖 [BibTeX]